Navigation Links
Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments
Date:11/7/2011

al sale of its system in the United States. For more information, please visit the Company's website at http://www.delcath.com/.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the time required to build inventory and establish commercial operations in Europe, CE Marking for the Generation Two system, the timing of our commercial launch in Europe, adoption, use and resulting sales, if any, for  CHEMOSAT in the EEA, our ability to successfully commercialize CHEMOSAT and the potential of the chemosaturation therapy as a treatment for patients with cancers in the liver, acceptability of the clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future Delcath's system for chemosaturation in the United States and foreign markets for the same or  other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for CHEMOSAT, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relating to the results of research and development projects and future clinical trials, and uncertainties regarding our ability to obtain f
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Delcath Systems to Report Third Quarter Progress and Conduct Conference Call
2. FDA Schedules Delcath Pre-New Drug Application Meeting Date
3. Delcath Announces Completion of Regulatory Notification Process in New Zealand
4. Delcath Announces Updated Efficacy Results From Phase 3 Trial of Chemosaturation for Melanoma Metastases in the Liver Presented at European Multidisciplinary Cancer Congress
5. Delcath to Present at the JMP Securities Healthcare Conference on September 28, 2011
6. Delcath Systems, Inc. Hosts Symposium on Chemosaturation at CIRSE Annual Meeting
7. Delcath Announces Top-Line Results From Metastatic Colorectal Cohort in Phase II Trial of Chemosaturation System
8. Delcath Announces Encouraging Top-Line Results From Hepatobiliary Cohort in Phase II Trial of Chemosaturation System
9. Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011
10. Delcath Systems to Report Second Quarter Progress Update and Conduct Conference Call
11. Delcath Systems, Inc. Announces the Completion of Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... CHESTERBROOK, Pa. , May 24, 2013  Auxilium ... that executive management will participate in the Deutsche Bank ... the Westin Boston Waterfront Hotel.  Mr. Adrian ... scheduled to present an overview of the Company and ... May 29, 2013.   (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ...
(Date:5/24/2013)... BEIJING , May 24, 2013  Sinovac ... leading provider of biopharmaceutical products in ... main operating subsidiary company of Sinovac, obtained the ... (GMP Certificate) from the China State and Food ... district bulk production plants, and its Changping filing ...
(Date:5/24/2013)... England and BOSTON , May 24, ... discovery and development company, is pleased to announce that it has ... to augment the Company,s business development capabilities in Japan ... more than 15 years of experience in business development, licensing and ... Sciences, Inc., Roche Pharma ( Japan ), Nippon Roche ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 4Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 2Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 3Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2
... MERCER ISLAND, Wash., Dec. 22, 2010 Renal Advantage and ... the third largest provider of dialysis services in the U.S., ... – terms of which were not disclosed – was completed ... serving more than 19,000 patients in 260 locations in 32 ...
... AstraZeneca (NYSE: AZN ... will discontinue the development of CERTRIAD™ (rosuvastatin calcium and fenofibric ... dyslipidemia. This means the co-development and license agreement with Abbott ... Complete Response Letter (CRL) for the CERTRIAD New Drug Application ...
Cached Medicine Technology:Renal Advantage and Liberty Dialysis Deal Completed 2Renal Advantage and Liberty Dialysis Deal Completed 3
(Date:5/25/2013)... Pompton Plains, NJ (PRWEB) May 25, 2013 ... Apple’s iPhone. The universal app version of Word Hunt ... Universal app versions of Concentration, Edge Match, Flash 2, Sudoku ... , The brain games’ gameplay and revolutionary lifetime brain ... and 4 inch displays. , “100 years of brain fitness ...
(Date:5/25/2013)... IBISWorld estimates that revenue for the Cell Therapy ... 28.7% to $1.0 billion in the five years to 2013, ... no new cell therapy products were introduced, according to IBISWorld ... period. In the years since, however, the Food and Drug ... to the industry's fast growth during the five years to ...
(Date:5/25/2013)... For college students, few events ... they are turning to prescription stimulants like Adderall ... more on this, go to http://www.sciencedaily.com/releases/2013/05/130501145151.htm . ... that students who pick up Adderall, “just to ... developing a physical and psychological dependency. While initially ...
(Date:5/25/2013)... Ayurveda is the traditional medicine of ... of life". While a medical science, its scope enters into ... Its fundamental philosophy is that disease is the end result ... that in order to re-establish optimal health, we must discover ... a life style which brings us back into harmony. , ...
(Date:5/25/2013)... Arizona (PRWEB) May 25, 2013 The current ... Center, their parents, and the B2B staff all came together ... everyone enjoyed an array of Indian Cuisine, the residents got ... company, for helping them on their road to recovery, and ... the Drug and Alcohol center in 2010 after realizing the ...
Breaking Medicine News(10 mins):Health News:Acuity Games Apps Come to the iPhone 2Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals 2Health News:Ayurveda Education Programs Offered by the California College of Ayurveda Include Panchakarma Certification, Practitioner Courses, and Body Therapy Classes 2Health News:Back2Basics Drug and Alcohol Rehabilitation Center Celebrates Their 3rd Anniversary 2
... Minneapolis for a one-day summit on Jan. 20, to ... (ICD) leads, which recently underwent a Class I FDA ... Mayo Clinic have organized the summit to develop a ... leads. Approximately 80,000 active patients have Riata or ...
... instance when the smaller sibling gets to call the shots ... has long been known to be a checkpoint in cell ... until their DNA has been fully replicated or repaired. Now ... of Technology have discovered a shorter form they,ve dubbed Chk1-S ...
... HealthDay Reporter , MONDAY, Jan. 2 (HealthDay News) ... at relieving neck pain in the long term than ... spinal manipulation therapy for neck pain also reported greater ... "We found that there are some viable ...
... Pirfenidone inhibits the development of inflammation and scarring (fibrosis) ... treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) ... assessment in accordance with the Act on the Reform ... Institute for Quality and Efficiency in Health Care (IQWiG) ...
... (Boston) - The first-ever published whole-genome sequences of not just ... that both unusual and common genetic phenomena contribute to the ... the study -- led by researchers from the Boston University ... -- will be available to researchers around the world at ...
... State University researchers one working at a medieval burial ... East Lansing have shown how modern science can unlock ... first to confirm the existence of brucellosis, an infectious disease ... findings, which appear in the American Journal of Physical ...
Cached Medicine News:Health News:Summit seeks to inform electrophysiologists on Riata ICD recall 2Health News:Smaller sibling protein calls the shots in cell division 2Health News:Spinal Manipulation, Home Exercise May Ease Neck Pain 2Health News:Spinal Manipulation, Home Exercise May Ease Neck Pain 3Health News:Spinal Manipulation, Home Exercise May Ease Neck Pain 4Health News:Pirfenidone: Extent of added benefit assessed 2Health News:Pirfenidone: Extent of added benefit assessed 3Health News:Genetic predisposition to disease common in 2 supercentenarians: New study 2Health News:Scientists crack medieval bone code 2
... BioControl multichannel has the ... the single channel model.The ... all seven multichannel and ... cone modules. Both pipettes ...
... in a wide variety of applications. • Whole ... can be freely rotated against the handle to ... an optimum angle towards the microtiter plate. • ... of most common pipette tips, and provides a ...
... value!, Comfortable feel and less hand ... Finer control while pipetting with smooth, light ... with long, lever tip ejector , Completely ... the need for recalibration , Easy-to-read precision ...
... Designed with 96-well plates in ... useful for molecular biology applications: PCR* ... 96-well plates, etc. Used with Diamond ... system, this product will maximize performance ...
Medicine Products: